News | January 08, 2025
Ajooni Biotech to raise Rs. 45 crore through convertible warrants
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Narayanan to lead SeQuent through next phase of consolidation and growth
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The consideration for the acquisition is US $ 2.25 million
The order strengthens the company’s position in the East African market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
